Arcadia Biosciences, Inc.
RKDAArcadia Biosciences, Inc. in brief
Arcadia Biosciences, Inc. is a listed company in the Agriculture Related industry, based in Dallas, Texas, USA. It was founded in 2002. Its market value was $1 M on 30 October 2026, which makes it the 27,997th largest listed company in the world and the 4,516th largest in the USA on this site. In the year to December 2025 it had sales of $5 M and a net loss of $2 M. By market, the largest shares of its 2025 sales came from USA (100%). Its shares trade under the symbol RKDA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Arcadia Biosciences, Inc.
Arcadia Biosciences (Nasdaq: RKDA) is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.
It has developed a reduced-gluten and enhanced starch variety of wheat under the name GoodWheat. Arcadia also has a joint venture with Bioceres called Verdeca, which has developed and is commercializing HB4 technology in soybeans that gained FDA approval in 2017. HB4 soybeans have increased yield up to 30% while being more resistant to abiotic stress such as drought.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Arcadia Biosciences, Inc. timeline
- 2002
- 🏁· approximateFounded
- 2009
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2015
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 15 May 2015; shares registered for exchange trading on 8 May 2015.
- 2020
- 💰Record revenue of $8 millionFY2020, the highest of the 8 years on record.
Events of Arcadia Biosciences, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,148 (Jan 2020) · #4,230 (Jan 2021) · #5,281 (Jan 2022) · #5,674 (Dec 2022) · #5,654 (Jul 2023) · #4,685 (Jan 2024) · #2,469 (Mar 2026) · #4,172 (Aug 2026) · #4,445 (Oct 2026) · #4,519 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.2×
- Price / book
- 0.2×
- Free cash flow yield
- -460.2%
- Net margin (TTM)
- -202.2%
- Operating margin
- -51.4%
- Return on equity
- -247.1%
- Liabilities / assets
- 36.8%
- Net debt
- $-29M
- Revenue growth
- -3.6%
- R&D / revenue
- 0.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $5M | -3.6% | $-3M | $-2M | -48.1% |
| Dec 2024 | $5M | +13.3% | $-4M | $-7M | -139.7% |
| Dec 2023 | $4M | -40.0% | $-6M | $-14M | -314.2% |
| Dec 2022 | $7M | +9.4% | $-14M | $-15M | -207.3% |
| Dec 2021 | $7M | -15.6% | $-36M | $-15M | -216.2% |
| Dec 2020 | $8M | +586.3% | $-13M | $-5M | -58.0% |
| Dec 2019 | $1M | -19.9% | $-19M | $-29M | -2461.5% |
| Dec 2018 | $1M | — | $-17M | $-13M | -923.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-5M | $0M | $-5M | $-1.71 | — |
| Dec 2024 | $-10M | $0M | $-10M | $-5.17 | — |
| Dec 2023 | $-15M | $0M | $-15M | $-11.29 | — |
| Dec 2022 | $-14M | $0M | $-14M | $-25.65 | — |
| Dec 2021 | $-26M | $1M | $-27M | $-27.56 | — |
| Dec 2020 | $-30M | $2M | $-33M | $-0.47 | — |
| Dec 2019 | $-17M | $1M | $-19M | $-4.53 | — |
| Dec 2018 | $-14M | $0M | $-14M | $-3.58 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $2M (+24.6% on a year earlier), net income $2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Sep 15, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Sep 4, 20268-KCurrent reportListing notice
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 10, 2026DEF 14AProxy statement
- Aug 10, 20268-KCurrent reportListing notice
- Jul 2, 20268-KCurrent reportDirectors or officers changed · Other events
- Jun 15, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations
Official filings of Arcadia Biosciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $5 M
- Operating income
- $-3 M
- Net income
- $-2 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $2 M
- Total equity
- $4 M
As of December-2025
Top 17 institutional investors in Arcadia Biosciences, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 476,422 | New | 7.86% | $0 M | Nov 16, 2026 |
| 2 | Two Sigma Securities, LLC | 30,904 | New | 0.51% | $0 M | Nov 16, 2026 |
| 3 | HRT Financial LP | 26,092 | -62,294 (-70.48%) | 0.43% | $0 M | Nov 13, 2026 |
| 4 | Jump Financial, LLC | 24,301 | New | 0.40% | $0 M | Nov 13, 2026 |
| 5 | Citadel Advisors LLC | 22,887 | -851 (-3.58%) | 0.38% | $0 M | Nov 16, 2026 |
| 6 | Geode Capital Management, LLC | 16,135 | 0 (0.00%) | 0.27% | $0 M | Nov 6, 2026 |
| 7 | State Street Corp | 12,146 | 0 (0.00%) | 0.20% | $0 M | Nov 12, 2026 |
| 8 | Vanguard Capital Management LLC | 9,644 | 0 (0.00%) | 0.16% | $0 M | Nov 13, 2026 |
| 9 | SBI Securities Co., Ltd. | 120 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 10 | TD Waterhouse Canada Inc. | 70 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 11 | UBS Group AG | 44 | +9 (+25.71%) | 0.00% | $0 M | Nov 10, 2026 |
| 12 | Group One Trading LLC | 18 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 13 | Pinnacle Financial Group, Inc. | 8 | — | 0.00% | $0 M | Nov 16, 2026 |
| 14 | Morgan Stanley | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 15 | Southern Michigan Bank & Trust | 2 | 0 (0.00%) | 0.00% | $0 M | Oct 19, 2026 |
| 16 | Barclays PLC | 1 | New | 0.00% | $0 M | Nov 6, 2026 |
| 17 | Caitong International Asset Management Co., Ltd | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Arcadia Biosciences, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 27,879 | $0 M | 0.46% | <0.01% | +304% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 9,644 | $0 M | 0.16% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,716 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 1,626 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Arcadia Biosciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Thomas J. SchaeferChief Executive Officer | Buy | +700 | $2.490 | $2 K | 2,819 | Form 4 |
| filed | Mark KawakamiChief Financial Officer | Buy | +700 | $2.490 | — | 2,681 | Form 4 |
| filed | Thomas J. SchaeferChief Executive Officer | Buy | +700 | $2.060 | $1 K | 2,119 | Form 4 |
| filed | Mark KawakamiChief Financial Officer | Buy | +700 | $2.060 | — | 1,981 | Form 4 |
| filed | Thomas J. SchaeferChief Financial Officer | Buy | +700 | $2.060 | $1 K | 1,419 | Form 4 |
| filed | Thomas J. SchaeferChief Financial Officer | Buy | +649 | $3.670 | $2 K | 719 | Form 4 |
| filed | Stanley Jacot Jr.Chief Executive Officer | Buy | +5,000 | $4.310 | $22 K | 5,000 | Form 4 |
| filed | Thomas J. SchaeferChief Financial Officer | Buy | +700 | $0.230 | $161 | 2,800 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Arcadia Biosciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split in the period to
Trading halts
- 2025-10-08 18:14 UTC, code LUDP, resumed 18:24 UTC
- 2025-10-08 18:09 UTC, code LUDP, resumed 18:14 UTC
- 2024-11-15 14:58 UTC, code LUDP, resumed 15:03 UTC
- 2024-11-15 14:53 UTC, code LUDP, resumed 14:58 UTC
Fails to deliver
- : 3,565 shares at $0.17
- : 18,415 shares at $0.20
- : 107,594 shares at $0.20
- : 840,555 shares at $0.21
- : 35,719 shares at $0.28
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Arcadia Biosciences, Inc. scorecard#
Passes 6 of the 19 checks that could be worked out: strongest in valuation (2 of 4), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.2×Price to book 0.2× against Agriculture Related's median of 1.7×.
- ✓Price to sales below its peers' median0.2×Price to sales 0.2× against Agriculture Related's median of 1.2×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-3.6%Revenue down 3.6% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-13.2%-13.2% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-13.2%-13.2% a year against Agriculture Related's median of -10.4% (14 companies).
- ✗Earnings per share grew in the newest year-1.71 vs -5.17Diluted EPS -1.71 in fiscal 2025 against -5.17 the year before (report's currency).
- ✓Net income higher than five years earlier-$2 M-$2 M in fiscal 2025 against -$5 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-51.4%-51.4% against Agriculture Related's median of 5.2% (14 companies).
- ✗Return on equity above 15%-45.2%-45.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-51.4%-51.4% in fiscal 2025 against -188.8% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities3.1×Current ratio 3.09 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-59.58Z-score -59.58 (distress zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.4%Diluted shares up 0.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Agriculture Related, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Arcadia Biosciences, Inc.'s statements, beside the median of Agriculture Related.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -51.4% | 5.2% | |
| Net margin | -48.2% | 3.5% | |
| Return on equity | -45.2% | 2.3% | |
| Revenue growth, 3 years a year | -13.2% | -10.4% | |
| Revenue growth | -3.6% | -3.8% | |
| Free cash flow margin | -97.5% | 8.0% |
2of 8on the Piotroski tests of financial strength
- Revenue fell 3.6% against the year before.
- Net loss of $2 million, the 12th loss-making year in a row.
- Free cash flow was negative: -$5 million.
Arcadia Biosciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 4.9−3.7%100% | 5.0+13.3%100% | 4.5r5.3−40.0%100% | 7.4r10.0+9.4%100% | 6.8−15.6%100% | 8.0+587%100% | 1.2−20.2%100% | 1.5−63.6%100% | 4.0+26.3%100% | 3.2—100% | |
| Cost of revenue | 3.1+4.6%63.8% | 3.0+36.3%58.7% | 2.2r3.3−64.4%48.8% | 6.1r9.8−29.9%82.2% | 8.7+67.5%128% | 5.2—64.7% | — | — | 0.3−68.4%7.0% | 0.9—28.1% | |
| Research and development | 0.0−83.0%0.2% | 0.1−17.2%1.1% | 0.1r1.4−95.8%1.4% | 1.5−61.2%20.3% | 3.9−51.1%57.4% | 8.0+12.1%99.1% | 7.1+17.0%607% | 6.1−18.1%415% | 7.4−14.5%184% | 8.7—272% | |
| Selling, general and administrative | 7.0−27.4%144% | 9.6+17.1%191% | 8.2r15−45.2%185% | 15r18−34.4%203% | 23+39.3%338% | 16+21.4%205% | 14+16.9%1161% | 12+8.9%793% | 11−13.1%265% | 12—384% | |
| Operating expenses | — | — | — | — | — | 21+1.3%259% | 21+12.1%1758% | 18−0.0%1252% | 18−15.9%456% | 22—684% | |
| Total costs and expenses | 7.4−15.4%151% | 8.7−17.6%172% | 11r19−50.7%237% | 21r29−49.4%289% | 42+103%624% | 21—259% | — | — | — | — | |
| Operating income | −2.5—−51.5% | −3.6—−72.3% | −6.1r−14—−137% | −14r−19—−189% | −36—−524% | −13—−159% | −19—−1658% | −17—−1152% | −14—−356% | −19—−584% | |
| Interest expense and finance costs | — | — | — | — | 0.0−57.4%0.3% | 0.0+840%0.6% | 0.0—0.4% | — | 0.7−43.4%18.6% | 1.3—41.4% | |
| Net interest income | 0.2−71.7%4.5% | 0.8+12.5%15.5% | 0.7+140%15.6% | 0.3—3.9% | −0.0—−0.3% | — | — | — | — | — | |
| Other non-operating income (expense) | 2.3+7348%47.5% | 0.0−35.4%0.6% | 0.0+433%1.1% | 0.0r0.0−99.9%0.1% | 10+1267%149% | 0.7+58.8%9.2% | 0.5+18.3%39.9% | 0.4+40.2%26.9% | 0.3−17.4%7.0% | 0.3—10.7% | |
| Income before tax | −2.3—−48.0% | −4.3—−85.4% | −5.3r−13—−119% | −11r−16—−146% | −16—−238% | −6.2—−76.5% | −29—−2470% | −13—−920% | −16—−389% | −20—−615% | |
| Income tax | 0.00.0%0.2% | 0.00.0%0.2% | 0.0−42.9%0.2% | 0.0+600%0.2% | 0.0—0.0% | −0.1−6300%−1.5% | 0.0−80.0%0.2% | 0.0−61.5%0.7% | 0.0+4.0%0.6% | 0.0—0.8% | |
| Income from discontinued operations | — | — | −0.8—−18.4% | −4.8—−64.5% | — | — | — | — | — | — | |
| Net income including minority interests | −2.3—−48.1% | −7.0—−140% | −14—−314% | −16—−210% | −16—−238% | −6.0—−75.0% | −29—−2470% | −13—−921% | — | — | |
| Minority interests' share of net income | — | 0—0.0% | −0.0—−0.1% | −0.2—−3.2% | −1.5—−21.7% | −1.4—−17.1% | −0.1—−5.8% | — | — | — | |
| Net income attributable to shareholders | −2.3—−48.1% | −7.0—−140% | −14—−314% | −15—−207% | −15—−216% | −4.7—−57.9% | −29—−2464% | −13—−921% | −16—−390% | −20—−616% | |
| Earnings per share, basic | -1.71—— | -5.17—— | -11.29—— | -25.65—— | -27.56r-0.69—— | -0.47—— | -4.53—— | -3.58—— | -7.28—— | -8.85r-0.44—— | |
| Earnings per share, diluted | -1.71—— | -5.17—— | -11.29—— | -25.65—— | -27.56r-0.69—— | -0.47—— | -4.53—— | -3.58—— | -7.28—— | -8.85r-0.44—— | |
| Shares, weighted average (basic) | 1.4+0.3%— | 1.4+10.2%— | 1.2+106%— | 0.6+12.7%— | 0.5—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 1.4+0.3%— | 1.4+10.2%— | 1.2+106%— | 0.6+12.7%— | 0.5r21−94.7%— | 10.0+56.5%— | 6.4+68.9%— | 3.8+74.7%— | 2.2−2.8%— | 2.2r44—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 0.3−93.9%4.0% | 4.2−34.9%31.4% | 6.5−68.4%33.1% | 21−28.0%71.4% | 29+104%65.3% | 14+66.8%29.7% | 8.4−29.8%25.8% | 12+31.5%49.9% | 9.1+353%55.1% | 2.0—3.6% | |
| Short-term investments | 4.3—65.8% | 0−100%0.0% | 5.1—26.0% | 0—0.0% | — | 12−31.3%24.6% | 17+72.2%51.9% | 9.8+152%40.9% | 3.9−92.0%23.5% | 49—85.8% | |
| Receivables | — | — | — | — | 1.4−2.6%3.1% | 1.4+134%3.0% | 0.6+265%1.8% | 0.2−86.6%0.7% | 1.2+253%7.4% | 0.3—0.6% | |
| Inventory | 1.2+34.1%18.5% | 0.9+8.0%6.7% | 0.8r2.0−63.9%4.2% | 2.3r2.6−47.6%8.0% | 4.4+16.3%10.1% | 3.8+112%8.1% | 1.8+891%5.5% | 0.2−21.0%0.8% | 0.2−9.1%1.4% | 0.3—0.4% | |
| Other current assets | 0.2−83.2%2.4% | 0.9+15.4%6.9% | 0.8+1.5%4.1% | 0.8r0.8−11.7%2.7% | 0.9+11.0%2.0% | 0.8+13.9%1.7% | 0.7+1.1%2.2% | 0.7+25.7%2.9% | 0.6−36.1%3.4% | 0.9—1.6% | |
| Current assets | 6.4−31.2%97.1% | 9.2−38.3%68.4% | 15−41.1%76.0% | 25−28.2%87.8% | 35+11.6%80.6% | 32+11.4%66.9% | 28+24.3%87.3% | 23+52.0%95.2% | 15−71.2%90.8% | 52—92.3% | |
| Property, plant and equipment | 0.0−80.5%0.1% | 0.0−41.4%0.3% | 0.1r0.4−89.7%0.4% | 0.7r0.7−70.3%2.4% | 2.3−35.3%5.2% | 3.5+96.7%7.5% | 1.8+355%5.5% | 0.4+32.1%1.6% | 0.3−41.1%1.8% | 0.5—0.9% | |
| Right-of-use (leased) assets | 0−100%0.0% | 0.1−82.7%1.0% | 0.8−57.1%4.0% | 1.8−40.0%6.4% | 3.1−47.1%7.0% | 5.8+197%12.3% | 2.0—6.0% | — | — | — | |
| Goodwill | — | — | — | — | — | 0.4—0.9% | — | — | — | — | |
| Other intangible assets | 0.00.0%0.6% | 0.00.0%0.3% | 0.0−2.5%0.2% | 0.0−91.7%0.1% | 0.5+30.8%1.1% | 0.4—0.8% | — | — | — | — | |
| Long-term investments | — | — | — | — | — | — | — | — | — | 2.5—4.4% | |
| Total assets | 6.5−51.6%100% | 14−31.4%100% | 20−31.9%100% | 29−34.1%100% | 44−7.2%100% | 47+45.4%100% | 33+35.6%100% | 24+45.0%100% | 17−70.7%100% | 57—100% | |
| Accounts payable | 1.5+107%22.2% | 0.7r0.7+44.9%5.2% | 0.5r0.8−46.4%2.5% | 0.9r0.9−35.9%3.1% | 1.4r1.4+94.4%3.2% | 0.7r0.7+47.6%1.5% | 0.5r0.5+72.6%1.5% | 0.3r0.3−22.1%1.2% | 0.4r0.4+64.9%2.2% | 0.2r0.2—0.4% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | 1.1+4654%2.4% | 0.0—0.1% | — | — | 0—0.0% | |
| Current liabilities | 2.1−19.7%31.5% | 2.6−28.6%19.0% | 3.6−14.7%18.2% | 4.2−16.5%14.6% | 5.0−20.2%11.5% | 6.3+10.6%13.3% | 5.7+86.9%17.5% | 3.1−13.4%12.7% | 3.5+12.7%21.3% | 3.1—5.5% | |
| Long-term debt | — | — | — | — | 0−100%0.0% | 2.1+1867%4.4% | 0.1—0.3% | — | — | 25—44.4% | |
| Lease liabilities (non-current) | — | 0−100%0.0% | 0.2−84.6%0.8% | 1.0−54.6%3.5% | 2.2−58.8%5.1% | 5.4+260%11.4% | 1.5—4.6% | — | — | — | |
| Total liabilities | 2.4−67.0%36.8% | 7.3+4.2%54.0% | 7.0−12.7%35.5% | 8.0−36.9%27.7% | 13−32.3%29.0% | 19−22.5%39.7% | 24+116%74.4% | 11+30.9%46.7% | 8.6−75.1%51.7% | 34—60.8% | |
| Retained earnings | −281—−4296% | −279—−2063% | −272—−1380% | −258—−892% | −226—−516% | −212—−447% | −207—−636% | −178—−742% | −167—−1009% | −152—−268% | |
| Shareholders' equity | — | 6.2−51.5%46.0% | 13−38.9%65.2% | 21−32.4%72.7% | 31+12.1%70.8% | 28+260%58.6% | 7.7−39.9%23.7% | 13+60.0%53.3% | 8.0−63.9%48.3% | 22—39.2% | |
| Minority interests | — | 0—0.0% | −0.1—−0.7% | −0.1−229%−0.5% | 0.1−87.5%0.2% | 0.8+33.2%1.7% | 0.6—1.9% | — | — | — | |
| Total equity | 4.1−33.5%63.2% | 6.2−51.0%46.0% | 13−39.2%64.5% | 21−33.0%72.3% | 31+9.3%71.0% | 29+243%60.3% | 8.3r8.3−35.0%25.6% | 13+60.0%53.3% | 8.0—48.3% | — | |
| Total liabilities and equity | 6.5−51.6%100% | 14−31.4%100% | 20−31.9%100% | 29−34.1%100% | 44−7.2%100% | 47+45.4%100% | 33+35.6%100% | 24+45.0%100% | 17−70.7%100% | 57—100% | |
| Shares outstanding | 1.4+0.6%— | 1.4+6.2%— | 1.3+109%— | 0.6+11.1%— | 0.6r22−95.9%— | 13+55.6%— | 8.6+81.1%— | 4.8+124%— | 2.1−4.1%— | 2.2r44—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | 0.2−44.8%10.5% | 0.3−8.2%6.9% | 0.3—9.5% | |
| Share-based compensation | 0.2−54.3%4.8% | 0.5−28.6%10.1% | 0.7−35.2%16.1% | 1.1−28.2%14.9% | 1.5−24.5%22.7% | 2.0−10.7%25.4% | 2.3+47.5%196% | 1.6+5.2%106% | 1.5+39.2%36.6% | 1.1—33.2% | |
| Cash from operating activities | −4.7—−97.6% | −9.6—−191% | −15—−343% | −14—−188% | −26—−382% | −30—−376% | −17—−1471% | −14—−931% | −14—−347% | −17—−535% | |
| Capital expenditure | 0—0.0% | −0.0—−0.3% | −0.0—−0.1% | −0.1—−1.0% | −1.0—−14.9% | −2.3—−29.1% | −1.5—−126% | −0.3—−17.1% | −0.1—−2.0% | −0.2—−7.2% | |
| Acquisitions, net of cash acquired | — | — | — | 0—0.0% | −4.3—−62.7% | −0.5—−6.2% | — | — | — | — | |
| Cash from investing activities | 0.8−89.8%15.4% | 7.3—146% | −4.3−407%−97.5% | 1.4−91.5%19.1% | 17−3.9%245% | 17—215% | −8.4—−716% | −6.0−113%−408% | 47—1172% | −5.3—−166% | |
| Cash from financing activities | 0.0−33.3%0.1% | 0.0−99.8%0.2% | 5.5+22.0%124% | 4.5−79.4%60.9% | 22+6.5%323% | 21−6.5%256% | 22−2.2%1881% | 22—1535% | −26−6691%−648% | 0.4—12.4% | |
| Change in cash | −4.0—−82.0% | −2.3—−45.1% | −14—−317% | −8.0−164%−108% | 13+65.8%186% | 7.6—94.9% | −3.6−225%−306% | 2.9−59.6%196% | 7.1—177% | −22—−689% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 5.1−2.1%100% | 1.6+24.3%100% | 1.4−0.8%100% | 1.1−8.3%100% | 0.9*−25.9%100% | 1.3−15.3%100% | 1.5+11.4%100% | 1.2+21.6%100% | 1.2*+56.5%100% | 1.5—100% | 1.3—100% | 1.0r1.3—100% | 0.8r1.2*—100% | |
| Cost of revenue | 3.0−7.3%58.9% | 0.8−14.0%46.9% | 0.8−1.5%56.3% | 0.7+2.6%63.6% | 0.7*−14.3%78.7% | 0.9−14.3%67.9% | 0.8+30.2%56.6% | 0.7+44.8%56.8% | 0.8*+365%68.0% | 1.0—67.1% | 0.6—48.5% | 0.5r0.8—47.7% | 0.2r0.7*—22.9% | |
| Research and development | — | 0—0.0% | 0−100%0.0% | — | 0*−100%0.0% | 0−100%0.0% | 0.0−10.0%0.6% | 0−100%0.0% | 0.0*+44.4%1.1% | 0.0—1.6% | 0.0—0.8% | 0.0r0.3—0.6% | 0.0r0.3*—1.2% | |
| Selling, general and administrative | 5.6−31.1%110% | 1.7+8.2%105% | 1.1−46.9%78.1% | 1.2−32.2%107% | 1.6*−41.0%174% | 1.6−29.9%121% | 2.1−20.9%146% | 1.7−15.7%145% | 2.7*+56.3%218% | 2.2—146% | 2.7—205% | 2.1r3.2—209% | 1.7r3.4*—219% | |
| Total costs and expenses | 8.6−0.3%169% | 2.5+0.2%152% | 1.9−0.9%134% | 1.9+180%171% | 2.3*−34.9%253% | 2.5−25.6%188% | 2.0—134% | 0.7−74.0%55.8% | 3.5*+77.4%287% | 3.3—215% | −0.7—−51.6% | 2.6r4.3—261% | 2.0r4.5*—254% | |
| Operating income | −3.5—−68.9% | −0.8—−51.8% | −0.5—−34.4% | −0.8−247%−70.8% | −1.4*—−153% | −1.2—−88.5% | −0.5−125%−34.4% | 0.5—44.2% | −2.3*—−187% | −1.8—−115% | 2.0—152% | −1.6r−3.1—−161% | −1.2r−3.4*—−154% | |
| Net interest income | 0.0−95.5%0.5% | 0.0+186%1.2% | 0.0−77.8%0.1% | 0.0−97.6%0.5% | −0.0*−100%−0.1% | 0.0−97.0%0.5% | 0.0−94.0%0.6% | 0.2+360%17.3% | 0.4*+125%29.1% | 0.2—15.2% | 0.2—11.5% | 0.0—4.6% | 0.2*—20.2% | |
| Other non-operating income (expense) | −4.7−280%−93.7% | 0−100%0.0% | −2.8−360%−193% | −1.5—−137% | −0.5*—−51.2% | 1.7+11220%130% | 1.1+614%73.6% | 0−100%0.0% | −0.1*−1242%−11.3% | 0.0—1.0% | 0.2—11.5% | 0.0—0.3% | 0.0*—1.5% | |
| Income before tax | — | — | — | — | — | — | — | — | −4.0*—−331% | −1.2—−76.9% | 1.9—142% | — | −0.4r−2.6*—−57.3% | |
| Income tax | — | — | — | — | — | — | — | — | 0.0*+14.3%0.7% | 0—0.0% | 0—0.0% | — | 0.0*—0.9% | |
| Income from discontinued operations | — | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | — | −0.4—−28.0% | −0.8—−60.4% | −1.5r0—−150% | −0.2*—−29.6% | |
| Net income including minority interests | −10—−202% | 1.8+105%108% | −6.3—−434% | −4.4−269%−399% | −1.3*—−148% | 0.9—65.7% | −4.5−520%−306% | 2.6—217% | −4.1*—−334% | −1.6—−105% | 1.1—81.2% | −2.4—−245% | −2.9*—−367% | |
| Minority interests' share of net income | — | — | — | — | — | — | — | — | 0*—0.0% | 0—0.0% | 0—0.0% | — | 0*—0.0% | |
| Net income attributable to shareholders | −10—−202% | 1.8+105%108% | −6.3—−434% | −4.4−269%−399% | −1.3*—−148% | 0.9—65.7% | −4.5−520%−306% | 2.6—217% | −4.1*—−334% | −1.6—−105% | 1.1—81.2% | −2.4—−245% | −2.9*—−367% | |
| Earnings per share, basic | — | 0.29−54.0%— | -2.09—— | -2.11−211%— | — | 0.63—— | -3.26−518%— | 1.90—— | — | -1.18—— | 0.78—— | -1.78—— | — | |
| Earnings per share, diluted | — | 0.29−53.2%— | -2.09—— | -2.11−211%— | — | 0.62—— | -3.26−518%— | 1.90—— | — | -1.18—— | 0.78—— | -1.78—— | — | |
| Shares, weighted average (basic) | 6.1+344%— | 6.1+344%— | 3.0+119%— | 2.1+52.5%— | — | 1.4+0.3%— | 1.4+0.3%— | 1.4+0.3%— | — | 1.4—— | 1.4—— | 1.4—— | — | |
| Shares, weighted average (diluted) | 6.1+342%— | 6.1+342%— | 3.0+119%— | 2.1+52.5%— | — | 1.4+0.6%— | 1.4+0.3%— | 1.4+0.3%— | — | 1.4—— | 1.4—— | 1.4—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2.8—60.3% | 2.8+154%60.3% | 4.2+204%70.9% | 1.0−69.8%17.9% | 0.3−93.9%4.0% | 1.1−71.5%13.0% | 1.4−75.0%17.7% | 3.2−4.8%24.3% | 4.2−34.9%31.4% | 3.9—25.8% | 5.5—31.7% | 3.3—20.7% | 6.5—33.1% | |
| Short-term investments | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 2.8—52.0% | 4.3—65.8% | 4.8+80.5%55.5% | 3.1+17.8%39.4% | — | 0−100%0.0% | 2.6—17.3% | 2.6—15.0% | 5.2—32.3% | 5.1—26.0% | |
| Inventory | 1.0—20.6% | 1.0−33.2%20.6% | 0.9−37.5%15.8% | 0.8−34.6%15.8% | 1.2+34.1%18.5% | 1.5+74.5%17.0% | 1.5+52.2%19.1% | 1.3−29.8%9.9% | 0.9+8.0%6.7% | 0.8—5.5% | 1.0—5.6% | 1.8—11.4% | 0.8r2.0—4.2% | |
| Other current assets | 0.1—2.5% | 0.1−43.9%2.5% | 0.1−81.2%1.2% | 0.2−74.7%3.5% | 0.2−83.2%2.4% | 0.2−58.9%2.5% | 0.4−28.7%4.9% | 0.7+35.9%5.6% | 0.9+15.4%6.9% | 0.5—3.4% | 0.5—3.1% | 0.5—3.3% | 0.8—4.1% | |
| Current assets | 4.6—96.7% | 4.6−45.6%96.7% | 5.7−24.3%97.4% | 5.2−41.6%97.1% | 6.4−31.2%97.1% | 8.4−21.7%97.7% | 7.6−39.0%97.3% | 8.8−24.0%68.1% | 9.2−38.3%68.4% | 11—70.3% | 12—71.6% | 12—72.6% | 15—76.0% | |
| Property, plant and equipment | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.0−80.5%0.1% | 0.0−81.8%0.1% | 0.0−77.8%0.2% | 0.0−91.5%0.2% | 0.0−41.4%0.3% | 0.1—0.4% | 0.1—0.3% | 0.3—2.0% | 0.1r0.4—0.4% | |
| Right-of-use (leased) assets | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0.0−98.1%0.1% | 0.0−97.3%0.1% | 0.1−82.7%1.0% | 0.3—2.0% | 0.5—3.0% | 0.7—4.3% | 0.8—4.0% | |
| Other intangible assets | 0.0—0.8% | 0.00.0%0.8% | 0.00.0%0.7% | 0.00.0%0.7% | 0.00.0%0.6% | 0.00.0%0.5% | 0.00.0%0.5% | 0.00.0%0.3% | 0.00.0%0.3% | 0.0—0.3% | 0.0—0.2% | 0.0—0.2% | 0.0—0.2% | |
| Total assets | 4.7—100% | 4.7−45.1%100% | 5.9−24.3%100% | 5.3−59.0%100% | 6.5−51.6%100% | 8.6−43.7%100% | 7.8−55.2%100% | 13−19.0%100% | 14−31.4%100% | 15—100% | 17—100% | 16—100% | 20—100% | |
| Accounts payable | 1.0—21.4% | 1.0−49.9%21.4% | 1.4−11.2%23.5% | 1.1−41.8%20.7% | 1.5+107%22.2% | 2.0+19.1%23.5% | 1.6−0.1%20.0% | 1.9+9.4%14.6% | 0.7r0.7+44.9%5.2% | 1.7—11.1% | 1.6—9.0% | 1.7—10.8% | 0.5r0.8—2.5% | |
| Current liabilities | 1.3—27.0% | 1.3−44.3%27.0% | 1.6−10.5%27.9% | 1.4−38.4%25.6% | 2.1−19.7%31.5% | 2.3−1.8%26.6% | 1.8−31.8%23.6% | 2.2−23.0%17.1% | 2.6−28.6%19.0% | 2.3—15.3% | 2.7—15.5% | 2.9—17.9% | 3.6—18.2% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0.0—0.1% | 0.0—0.1% | 0.2—0.8% | |
| Total liabilities | 2.3—49.0% | 2.3−26.4%49.0% | 5.3+61.6%89.3% | 2.4−40.3%45.8% | 2.4−67.0%36.8% | 3.1−38.3%36.6% | 3.3−43.9%41.8% | 4.1−26.6%31.4% | 7.3+4.2%54.0% | 5.1—33.4% | 5.8—33.4% | 5.6—34.7% | 7.0—35.5% | |
| Retained earnings | −290—−6152% | −290—−6152% | −292—−4953% | −286—−5365% | −281—−4296% | −280—−3260% | −281—−3605% | −276—−2127% | −279—−2063% | −275—−1803% | −273—−1573% | −274—−1709% | −272—−1380% | |
| Shareholders' equity | — | — | — | — | — | — | — | — | 6.2−51.5%46.0% | 10—67.5% | 12—67.4% | 11—66.2% | 13—65.2% | |
| Minority interests | — | — | — | — | — | — | — | — | 0—0.0% | −0.1—−0.9% | −0.1—−0.8% | −0.1—−0.9% | −0.1—−0.7% | |
| Total equity | 2.4—51.0% | 2.4−55.9%51.0% | 0.6−86.0%10.7% | 2.9−67.6%54.2% | 4.1−33.5%63.2% | 5.4−46.4%63.4% | 4.5−60.8%58.2% | 8.9−15.1%68.6% | 6.2−51.0%46.0% | 10—66.6% | 12—66.6% | 10—65.3% | 13—64.5% | |
| Total liabilities and equity | 4.7—100% | 4.7−45.1%100% | 5.9−24.3%100% | 5.3−59.0%100% | 6.5−51.6%100% | 8.6−43.7%100% | 7.8−55.2%100% | 13−19.0%100% | 14−31.4%100% | 15—100% | 17—100% | 16—100% | 20—100% | |
| Shares outstanding | 5.1—— | 5.1+275%— | 2.2+59.6%— | 2.1+50.5%— | 1.4+0.6%— | 1.4+0.2%— | 1.4+0.3%— | 1.4+0.3%— | 1.4+6.2%— | 1.4—— | 1.4—— | 1.4—— | 1.3—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.1−82.0%1.2% | 0.0−73.6%0.9% | 0.0−83.7%1.0% | 0.0−80.8%1.4% | 0.0*−85.5%1.9% | 0.1−65.8%4.1% | 0.1−15.7%5.9% | 0.1−43.5%6.5% | 0.1*−18.8%9.6% | 0.2—10.1% | 0.1—7.8% | 0.1—14.0% | 0.1*—18.5% | |
| Cash from operating activities | −3.6—−70.3% | −1.3*—−79.0% | −0.3*—−22.1% | −1.1—−99.9% | −0.9*—−95.6% | −0.3*—−19.7% | −2.0*—−140% | −1.6—−132% | −2.2*—−182% | −1.8*—−114% | −2.5*—−188% | −3.2—−325% | −4.1*—−533% | |
| Capital expenditure | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | −0.0*—−0.2% | −0.0—−1.3% | 0*—0.0% | |
| Cash from investing activities | 0−100%0.0% | 0*—0.0% | 0*−100%0.0% | 0−100%0.0% | 0*−100%0.0% | 0*−100%0.0% | 0.3*−94.6%17.2% | 0.5+12400%41.7% | 2.5*+4737%207% | 0.2*—11.7% | 4.6*—356% | 0.0—0.4% | 0.1*—6.7% | |
| Cash from financing activities | 5.3+87933%104% | −0.1*−5600%−3.4% | 3.5*—246% | 1.8+35780%163% | 0*—0.0% | 0.0*−75.0%0.1% | 0*—0.0% | 0.00.0%0.4% | 0*—0.0% | 0.0*—0.3% | 0*—0.0% | 0.0—0.5% | 0*—0.0% | |
| Change in cash | 1.7—34.1% | −1.3*—−82.4% | 3.2*—223% | 0.7—63.2% | −0.9*−381%−95.6% | −0.3*—−19.7% | −1.8*−182%−123% | −1.1—−90.3% | 0.3*—25.2% | −1.6*—−102% | 2.2*—167% | −3.2—−324% | −4.1*—−527% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Arcadia Biosciences, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$5 M100%-3.0%
Countries and regions
- 🇺🇸 USA$5 M100%-0.8%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Arcadia Biosciences, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $469 K | $380 K | $218 K | $36 |
| 2024Chief executive | $518 K | $532 K | $263 K | — |
| 2023Chief executive | $525 K | $488 K | $363 K | $8 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Arcadia Biosciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 2 · Auditor changed 1 · Change in control 1 · Directors and officers 6 · Material agreement 5 · Agreement ended 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share saleShareholder rights changed | 8-K | |
| Agreement ended | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Change in controlDirectors and officersMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K/A |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 acquisitions · 3 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Anawah, Inc | Jun 2005 | Jun 2005 | — | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2026 | $4 M | Private placement after listing | $2 to $10 million | 5 | equity, options | SEC |
| Jan 2026 | $2 M | Private placement after listing | $2 to $10 million | 3 | equity, options | SEC |
| Jan 2021 | $25 M | Private placement after listing | $10 to $50 million | 26 | equity, options | SEC |
| Mar 2018 | $10 M | Private placement after listing | $10 to $50 million | 2 | equity, options | SEC |
| Mar 2014 | $19 M | No. 3 | $10 to $50 million | 8 | equity, options | SEC |
| Oct 2009 | $2 M | No. 2 | $2 to $10 million | 6 | equity | SEC |
| Jul 2008 | $15 M | No. 1 | $10 to $50 million | 9 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Arcadia Biosciences, Inc.#
2 labor condition applications certified in fiscal 2021 for 2 positions, at a median wage of $94 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| MANAGER DEMAND AND SUPPLY PLANNINGTransportation, Storage, and Distribution Managers | 2 | $94 K |
Where: Davis, CA 2
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as ARCADIA BIOSCIENCES, INC.
How Arcadia Biosciences, Inc. compares in Agriculture Related
- Market cap$1 M · higher than 1% of 172
- Revenue$5 M · higher than 2% of 51
- Net margin-202.2% · higher than 0% of 49
- Revenue growth-3.6% · higher than 55% of 21
- Price / sales0.2× · lower than 94% of 49
- Price / book0.3× · lower than 93% of 42
Peer comparison · Agriculture Related
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Arcadia Biosciences, Inc.🇺🇸 | $1 M | — | -202.2% | -3.6% |
| Corteva, Inc.🇺🇸 | $51.2 B | 67.4× | 4.3% | +2.9% |
| Nutrien Ltd.🇨🇦 | $33.0 B | 14.6× | 8.4% | +3.5% |
| Qinghai Salt Lake Industry Co., Ltd🇨🇳 | $22.2 B | 18.1× | 54.7% | — |
| Zangge Holding Company🇨🇳 | $18.1 B | 32.4× | — | — |
| CF Industries Holdings, Inc.🇺🇸 | $17.7 B | 6.9× | 32.2% | +19.3% |
| Saudi Arabian Fertilizers Company🇸🇦 | $15.5 B | 13.5× | 33.0% | -17.3% |
| Yara International ASA🇳🇴 | $11.4 B | 8.3× | 8.8% | — |
| Shandong Hualu-Hengsheng Chemical Co., Ltd.🇨🇳 | $8.4 B | 17.5× | 10.7% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, Wikidata, value.today research, Wikipedia, Wikimedia Commons, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Arcadia Biosciences, Inc.? Verify and update this profile — free
Show Arcadia Biosciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.